Lonza to stop producing Moderna Covid-19 vaccine
Swiss pharmaceutical supplier Lonza will stop production of the Covid-19 vaccine for Moderna at its Visp site in the third quarter of 2023. Moderna will cover its demand for the vaccine from its own production facilities in the future, the US company announced on Tuesday.
US vaccine maker Moderna is focusing production of the mRNA agent at fewer sites as demand has declined with the transition from a pandemic to an endemic market, the statementExternal link added. Lonza could not initially be reached for comment by the Swiss business news agency AWP.
+ How Lonza became a big player in the production of Covid-19 vaccines
Moderna will meet vaccine demand for 2024 and 2025 from its own sites in Norwood, Massachusetts, it said. More capacity will be added starting in 2025 when Moderna’s new mRNA production facilities in the UK, Canada and Australia come online, according to the statement.
This news story has been written and carefully fact-checked by an external editorial team. At SWI swissinfo.ch we select the most relevant news for an international audience and use automatic translation tools such as DeepL to translate it into English. Providing you with automatically translated news gives us the time to write more in-depth articles. You can find them here.
If you want to know more about how we work, have a look here, and if you have feedback on this news story please write to english@swissinfo.ch.
In compliance with the JTI standards
More: SWI swissinfo.ch certified by the Journalism Trust Initiative
You can find an overview of ongoing debates with our journalists here. Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.